

Fig. 1






Fig. 2



1. Molecular weight marker
2. hCDCP1-ECD protein/reducing condition
3. After plasmin cleavage treatment/reducing condition
4. hCDCP1-ECD protein/non-reducing condition
5. After plasmin cleavage treatment/non-reducing condition



Fig. 3



- anti-CDCP1 (R&D systems)
- anti-c-Myc tag (Wako)
- - - - Isotype control (mouse IgG1)

Fig. 4

A



B




Fig. 5




Fig. 6A




Fig. 6B




Fig. 7




Fig. 8




Fig. 9






Fig. 10A



Horizontal axis: PE fluorescence intensity
Solid line: anti-CDCP1 antibody
Dotted line: non-specific IgG

Fig. 10B



Horizontal axis: PE fluorescence intensity
Solid line: anti-CDCP1 antibody
Dotted line: non-specific IgG

Fig. 11





Fig. 12



Horizontal axis: PE fluorescence intensity

———— anti-CDGP1 clones
..... No antibody

Fig. 13




Fig. 14




Fig. 15




Fig. 16




Fig. 17

A

IC₅₀ (M)

Cells	mh12A041-PBD	mh14A025-PBD	mh14A043-PBD	mh14A063-PBD	hIgG-PBD
SK-OV-3	1.36E-09	2.63E-11	4.17E-11	3.57E-10	7.10E-09
OVCAR3	2.15E-10	3.41E-12	4.86E-12	6.46E-11	2.02E-09
H358	5.27E-11	5.69E-12	8.28E-12	1.67E-11	3.29E-09
MDA-MB-231	5.56E-11	1.41E-11	4.01E-11	4.16E-11	9.42E-09
HCC1143	2.87E-11	4.65E-12	5.14E-12	1.29E-11	4.04E-09
SK-MES-1	1.10E-10	2.19E-11	4.32E-11	5.24E-11	8.36E-09
TFK-1	7.29E-11	1.58E-11	2.75E-11	5.19E-11	1.10E-08
Capan-2	1.48E-10	8.82E-12	1.01E-11	1.46E-11	7.84E-09
DLD1	4.42E-11	8.36E-12	1.37E-11	3.48E-11	8.56E-09
DU145	1.27E-10	2.57E-11	3.91E-11	5.76E-11	2.74E-08
PC3	2.21E-10	2.93E-11	5.26E-11	8.89E-11	4.51E-08
NHEK	4.12E-09	4.45E-09	4.02E-09	5.04E-09	2.94E-08
HMEpC	1.49E-08	9.57E-09	3.00E-09	4.38E-09	7.38E-08

B




Fig. 18




Fig. 19




Fig. 20




Fig. 21

